Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy

PHASE4CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

January 31, 2005

Study Completion Date

May 31, 2006

Conditions
Diabetic Peripheral Neuropathy
Interventions
DRUG

Pregabalin

Trial Locations (29)

12205

Pfizer Investigational Site, Albany

14618

Pfizer Investigational Site, Rochester

14642

Pfizer Investigational Site, Rochester

16635

Pfizer Investigational Site, Duncansville

27834

Pfizer Investigational Site, Greenville

33351

Pfizer Investigational Site, Sunrise

33401

Pfizer Investigational Site, West Palm Beach

33407

Pfizer Investigational Site, West Palm Beach

33410

Pfizer Investigational Site, Palm Beach Gardens

34471

Pfizer Investigational Site, Ocala

34474

Pfizer Investigational Site, Ocala

43623

Pfizer Investigational Site, Toledo

68116

Pfizer Investigational Site, Omaha

68131

Pfizer Investigational Site, Omaha

71913

Pfizer Investigational Site, Hot Springs

75230

Pfizer Investigational Site, Dallas

75246

Pfizer Investigational Site, Dallas

77030

Pfizer Investigational Site, Houston

78229

Pfizer Investigational Site, San Antonio

80218

Pfizer Investigational Site, Denver

84108

Pfizer Investigational Site, Salt Lake City

84132

Pfizer Investigational Site, Salt Lake City

89102

Pfizer Investigational Site, Las Vegas

90502

Pfizer Investigational Site, Torrance

90509

Pfizer Investigational Site, Torrance

92037

Pfizer Investigational Site, La Jolla

02115

Pfizer Investigational Site, Boston

07631

Pfizer Investigational Site, Englewood

08903

Pfizer Investigational Site, New Brunswick

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00159731 - Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy | Biotech Hunter | Biotech Hunter